European Psychiatry - Volume 41 - April 2017

390 / 916

S386 25th European congress of psychiatry / European Psychiatry 41S (2017) S365–S404
correlations for the sub groups with clinically detectable OCSs
(YBOCS > 8) and clinically significant OCSs (YBOCS > 14).
Results The only significant correlationwas that of scores of OCSs
withPANSS general psychopathology scores (rho = 0.190, P = 0.047).
Obsessions and compulsions did not significantly correlate with
positive or negative symptom clusters. No significant correlation
between OCSs and schizophrenia symptoms were detected in the
subgroups with clinically detectable or significant OCSs.
Conclusions OCSs appear to be a separate symptom cluster in the
context of schizophrenia, suggesting that OCSs cannot be expected
to be influenced by standard antipsychotic treatments.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0812
Obsessive compulsive symptoms,
social functioning and executive
functions in chronic schizophrenia
E. Theochari ∗, E. Tsaltas , D. Kontis
1 Psychiatric Hospital of Attica “Dromokaiteio”, Tarsi, Athens
Chaidari, Greece
2 Athens University Medical School, Experimental Psychology
Laboratory, 1st Department of Psychiatry, Athens, Greece
3 Psychiatric Hospital of Attica, Cognitive Rehabilitation Unit, Athens,
Greece
∗ Corresponding author.
Introduction Schizophrenia leads to functional deficits. A third
of schizophrenia patients have obsessive compulsive symptoms
(OCSs). The existing studies, which have investigated the effect
of OCSs on social functioning (SF) of schizophrenia patients have
produced contradictory findings and, interestingly, they have not
adjusted for the role of executive functioning.
Objectives To investigate the predictive role of OCSs on SF in
schizophrenia controlling for the effects of executive functioning.
Methods In a cross-sectional study of 110 chronic schizophrenia
patients we assessed OCSs (Yale-Brown Scale), SF (Strauss Carpen-
ter Scale) and composite executive function (cognitive flexibility:
Intra–extra dimensional set shifting task and planning: Stockings
of Cambridge task) using the Cambridge Neuropsychological Test
Automated Battery (CANTAB). We also measured total symptoms
(PANSS total scores) and illness duration. Regression analysis tested
the predicting role of OCSs (YBOCS total score) on functioning tak-
ing into account executive function (composite score) duration of
illness and schizophrenia symptoms.
Results OCSs were associated with better SF (B = 0.099; 95%
CI = 0.019, 0.180; t = 2.449; df = 88; P = 0.016). This result was driven
by the association of OCSs with job functioning (B = 0.043; 95%
CI = 0.006, 0.081; t = 2.289; df = 88; P= 0.024). Executive functions
were not significantly associated with social functioning.
Conclusions OCSs andnot executive functions are associatedwith
social functioning in schizophrenia. Future studies should exam-
ine whether OCSs represent a compensatory mechanism aiming at
preserving social functioning in the disorder.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0813
Real-world effectiveness of
antipsychotic treatments among
patients with schizophrenia and
affective symptoms
J. Tiihonen ∗, M. Lähteenvuo , F. Hoti , P. Vattulainen ,
H. Taipale , A. Tanskanen
1 Karolinska Institutet, Department of Clinical Neuroscience,
Stockholm, Sweden
2 University of Eastern Finland, Department of Forensic Psychiatry,
Kuopio, Finland
3 Epid Research, Pharmacoepidemiologic Research, Espoo, Finland
4 University of Eastern Finland, Kuopio Research Centre of Geriatric
Care, Kuopio, Finland
∗ Corresponding author.
Introduction The clinical distinction between schizophrenia and
affective psychoses is often not clear-cut, and very little is known
about the effectiveness of treatments among patients having both
schizophrenia and affective symptoms.
Objectives To study the comparative real-world effectiveness of
antipsychotic treatments among patients having schizophrenia and
affective symptoms.
Methods We studied the risk of all-cause rehospitalizationduring
use of specific antipsychotics during 1996–2012 among all patients
who had been previously hospitalizedwith both schizophrenia and
mood disorder diagnoses in Finland since 1987 (n = 28,015). We
linked nation-wide databases on hospitalization, mortality, and
filled prescriptions. The primary analysis was within-individual
analysis, in which each individual was used as his/her own
control to eliminate selection bias. The effect of concomitant psy-
chotropic medications, and the temporal orders of exposure and
non-exposure periods were adjusted.
Results When 22 specific antipsychotic treatments were com-
pared with the most frequently used antipsychotic quetiapine, the
lowest rehospitalization risks were observed during the treatment
periods of olanzapine long-acting injection (LAI) (HR: 0.52; 95% CI:
0.34–0.80), risperidone LAI (0.67; 0.56–0.81), and clozapine (0.68;
0.63–0.74). The worst outcome was observed for periciazine (1.19;
0.96–1.48) and no antipsychotic use (1.09; 1.04–1.13).
Conclusions Olanzapine LAI, risperidone LAI, and clozapine use
are associated with the lowest risk of rehospitalization among
patients with schizophrenia and affective symptoms.
Disclosure of interest Jari Tiihonen has served as a consultant to
The Finnish Medicines Agency Fimea, AstraZeneca, Bristol-Myers
Squibb, Eli Lilly, F. Hoffman-La Roche, Janssen-Cilag, Lundbeck,
Organon, and Finnish Medicines Agency he has received fees for
giving expert testimony to AstraZeneca, Bristol-Myers Squibb, Eli
Lilly, GlaxoSmithKline, Janssen-Cilag, Lundbeck, Otsuka and Pfizer
lecture fees from AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Glax-
oSmithKline, Janssen-Cilag, Lundbeck, Novartis, Otsuka, Pfizer and
grants from Stanley Foundation and Sigrid Jusélius Foundation.
Tiihonen is a member of advisory boards for AstraZeneca, Eli Lilly,
Janssen-Cilag, and Otsuka, and has research collaboration with
Lilly and Janssen. Markku Lähteenvuo is a major shareholder and
board member at Genomi Solutions ltd, a Finnish based bioinfor-
matics company. He has also received research grants or awards
from Boehringer-Ingelheim, and is working as a coordinator for
a research project funded by the Stanley Foundation. Fabian Hoti
and Pia Vattulainen are employed by EPID Research, which is a
contract research organization that performs commissioned phar-
macoepidemiological studies and thus its employees have been and
currently are working in collaborationwith several pharmaceutical
companies. Antti Tanskanen and Heidi Taipale have participated in
research projects funded by Janssenwith grants paid to the Karolin-
ska Institutet.